# Macmillan Cancer Support

> Macmillan Cancer Support is a VC fund backing Health Care and Biotechnology. See 9 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: London, United Kingdom
- Total investments: 9
- Last investment: Mar 2026
- Lead investor: 22%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/25599
- X (Twitter): https://twitter.com/macmillancancer
- Website: http://www.macmillan.org.uk/
- Facebook: https://www.facebook.com/macmillancancer

Macmillan Cancer Support is a VC fund in London focused on Health Care and Biotechnology. At Macmillan, They know how a cancer diagnosis can affect everything. So They’re here to support you and help you take back some control in your life. From help with money worries and advice about work, to someone who’ll listen if you just want to talk, we’re here.

## Contacts

5 contacts available for Macmillan Cancer Support. Shizune tracks 1 team members at Macmillan Cancer Support. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/macmillan-cancer-support?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 6 | 67% |
| Biotechnology | 4 | 44% |
| Medical | 2 | 22% |
| Machine Learning | 2 | 22% |
| Software | 1 | 11% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 3 | 33% |
| Series A | 2 | 22% |
| Funding Round | 2 | 22% |
| Series C | 1 | 11% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Andrew Hunter | Digital Ambassador | 0 | https://shizune.co/investors/profile/andrew-hunter |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Lucida Medical | Software to support analysis of MRI for cancer diagnosis, screening and management. Pi(tm), the company's first product, supports diagnosis of prostate cancer using multiparametric or diffusion MRI and is a CE marked medical device. We are interested to speak with investors and hospital partners who share our vision to find cancer early. | $11.5M | Series A | Mar 30, 2026 |  |
| Infinitopes | Infinitopes is a cancer research organization whose mission is to strengthen the immune system so that it can stop metastases and save lives. The company's platform creates healthcare systems and therapy designs to integrate high-efficiency vector delivery systems with optimal tumor target identification technologies in early-stage clinicaltrials, allowing patients to prevent cancer and tumors from taking their lives | $15.4M | Seed | Jan 21, 2026 |  |
| Perci Health | Perci Health provides telehealth services to people living with cancer. Our mission is to change perceptions about life after treatment. | $4.1M | Seed | Jun 11, 2025 |  |
| Dxcover | Dxcover is a clinical-stage liquid biopsy firm that is developing diagnostics for the early diagnosis of numerous malignancies, when treatment has a better possibility of having an influence on outcomes. The business was the first to use infrared spectroscopy of circulating pan-omic indicators to detect and identify cancer. The business hasgenerated compelling clinical data on the diagnosis of Stage I and Stage II malignancies with high accuracy.Dxcover was established in 2016 in Glasgow, Glasgow City by David S Palmer, Holly Butler, and Matthew Baker. | $6.2M |  | Feb 03, 2025 |  |
| 52 North Health | 52 North Health aims to improve healthcare with a medical device that uses artificial intelligence (AI) to determine the risk of neutropenic sepsis for patients undergoing chemotherapy. | $6M |  | Dec 03, 2024 |  |
| Leo Cancer Care | Leo Cancer Care develops radiation therapy technologies that support cancer treatment in an upright patient position. The company designs integrated imaging, patient positioning, and treatment systems that are compatible with fixed radiation beam platforms used in photon and particle therapy. Its technology focuses on supporting the radiotherapyworkflow from patient simulation through treatment while enabling multiple radiation therapy modalities. Leo Cancer Care also collaborates with healthcare providers, research institutions, and industry partners to evaluate and advance the clinical use of upright radiotherapy systems. In addition to developing treatment technologies, the company works on expanding access to radiotherapy through solutions that aim to improve workflow efficiency and compatibility with existing treatment infrastructure. |  | Series C | Jun 11, 2024 |  |
| 52 North Health | 52 North Health aims to improve healthcare with a medical device that uses artificial intelligence (AI) to determine the risk of neutropenic sepsis for patients undergoing chemotherapy. | $120.5K | Seed | Feb 07, 2023 |  |
| 52 North Health | 52 North Health aims to improve healthcare with a medical device that uses artificial intelligence (AI) to determine the risk of neutropenic sepsis for patients undergoing chemotherapy. | $120.5K | Seed | Feb 07, 2023 |  |
| OxCan | OxCan is a startup that uses machine learning and liquid biopsy for early lung cancer detection. | $11M | Series A |  |  |

9 of 9 investments shown.

## Co-investors
- [Cancer Research Horizons](https://shizune.co/investors/profile/cancer-research-technology) — VC Fund, 3 deals together
- [Meridian Health Ventures](https://shizune.co/investors/profile/khp-ventures) — VC Fund, 3 deals together
- [Crista Galli Ventures](https://shizune.co/investors/profile/crista-galli-ventures) — VC Fund, 2 deals together
- [Eos](https://shizune.co/investors/profile/eos-advisory) — VC Fund, 2 deals together
- [Octopus Ventures](https://shizune.co/investors/profile/octopus-ventures) — VC Fund, 2 deals together
- [OKG Capital](https://shizune.co/investors/profile/omg-capital-3255) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Macmillan Cancer Support invest in?

Macmillan Cancer Support invests primarily in Health Care, Biotechnology and Medical startups, most often at Seed and Series A stage. Most of the 9 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Macmillan Cancer Support?

Public channels for Macmillan Cancer Support include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Macmillan Cancer Support?

The team at Macmillan Cancer Support includes Andrew Hunter (Digital Ambassador). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co